title: [Nephrology: news in renal transplantation].
abstract: The selection of potential living donors will have to consider the latest data on risk factors for morbidity and mortality when a first degree relationship exists with a recipient in end-stage renal disease of unknown, and for women of childbearing age. Renal transplant patients with active hepatitis C of unknow origin will benefit from new antivirals without the risk of acute rejection. Preemptive CYP3A5 genotyping and extended-release tacrolimus formulations should allow the prescription of a suitable dose of tacrolimus immediately and avoid overexposure as a source of nephrotoxicity. The place of everolimus and belatacept in the panel of immunosuppressive treatments is being defined, based on infectious and immunologic risk factors.
authors: Yassine
authors: Y
authors: Bouatou
authors: Karine
authors: K
authors: Hadaya
mesh_terms: D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation; D019520:Living Donors; D009392:Nephrectomy / Q000401:mortality; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: D007166:Immunosuppressive Agents; D058570:TOR Serine-Threonine Kinases